Kairos Pharma Highlights CL-741 Acquisition and 2026 Clinical Milestones: A Strategic Analysis for Pharma Decision-Makers
Decision brief
Answer first · skim in under a minute
Kairos Pharma has signed a term sheet to acquire CL-741, a clinical-stage oncology asset, and outlined key 2026 milestones including a Phase 1 trial initiation. This article provides a competitive benchmarking analysis for pharma strategists and investors, covering the deal's rationale, pipeline impact, and what to watch next.
Kairos Pharma Highlights CL-741 Acquisition plans after signing a term sheet for a Phase 1-ready oral c-MET kinase inhibitor. Here is what the Business Wire and SEC disclosures say about 2026 clinical milestones—and what is still unfinished.
Contents10 sections
Key Takeaways
- On February 26, 2026, Kairos announced a term sheet with Celyn Therapeutics for worldwide rights to CL-741, a Phase 1-ready type IIb c-MET inhibitor, and CL-273, a pan-EGFR asset.
- An SEC Exhibit 99.1 shareholder update later focused on initiating a Phase 1 study of CL-741 in EGFR-mutated lung cancer during 2026.
- Consideration structures disclosed for related Celyn term sheets include equity issuance and milestone economics; closing remains subject to definitive agreements.
- ClinicalTrials.gov still shows limited Kairos-named interventional inventory for CL-741, so BD teams should treat Phase 1 start as a forward-looking milestone, not a completed enrollment event.
What did Kairos disclose about the CL-741 deal?
According to the February 26, 2026 Business Wire release, Kairos Pharma (NYSE American: KAPA) signed a term sheet to acquire worldwide rights to CL-273 and CL-741 from Celyn Therapeutics.
CL-741 is described as an orally available, selective type IIb c-MET kinase inhibitor aimed at MET exon 14 skipping and MET amplification settings in solid tumors, with NSCLC as a primary focus. The same package was furnished on SEC EDGAR as Exhibit 99.1.
Which 2026 milestones did management highlight?
A later shareholder letter on EDGAR lists planned milestones that include starting a Phase 1 study with CL-741 in EGFR-mutated lung cancer, continuing ENV-105 prostate and NSCLC work, and seeking collaborations around ENV-105 combinations. See the SEC Exhibit 99.1 milestones letter.
- CL-741 Phase 1 initiation targeting EGFR-mutated lung cancer in 2026
- ENV-105 prostate cancer randomized Phase 2 site expansion
- ENV-105 NSCLC Phase 1 safety and efficacy updates targeted by Q3 2026
How should investors read “term sheet” versus closed deal?
A term sheet is not closing. Financing conditions, NYSE American share-issuance caps, and definitive asset-purchase agreements can still break or reshape economics. Related Celyn disclosures on EDGAR describe equity percentages, a $15 million NDA/BLA milestone concept for another asset, and royalty constructs—useful comparables, not CL-741 cash guidance.
What remains unproven clinically?
No registrational efficacy for CL-741 is established in these filings. Phase 1-ready status means chemistry and preclinical packages may support first-in-human dosing, not that tumor response rates are known. Until an NCT ID and protocol synopsis post, treat efficacy language in secondary coverage as speculative.
Cross-check any claimed trial with a ClinicalTrials.gov Kairos Pharma search before updating pipeline databases.
What should oncology BD teams watch next?
Watch for a definitive purchase agreement, IND clearance or CTA acceptance for CL-741, first-patient-dosed notices, and whether Kairos keeps both EGFR and c-MET assets or partners one. Those events change valuation more than marketing language about a $16.2B EGFR market size cite.
Pipeline fit: CL-741 beside ENV-105 and related assets
Kairos has described ENV-105 programs in prostate cancer and NSCLC alongside the CL-741 term sheet. That dual focus can help a small oncology company stay visible with investigators, but it also stretches cash and bandwidth.
BD counterparties should ask whether CL-741 will be developed alone or as part of EGFR/MET sequencing strategies with CL-273. Combination ambition without financed Phase 1 slots is a common failure mode in micro-cap oncology.
Until definitive agreements close, model CL-741 as contingent. Assign probability-weighted ownership and do not consolidate peak-sales forecasts as if the asset were already on the balance sheet.
Related NovaPharma coverage
- ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution
- FDA Delays Decision on AstraZeneca Camizestrant
- Eli Lilly Gene Therapy Cholesterol Deals
Frequently Asked Questions
What is CL-741?
CL-741 is a Phase 1-ready, orally available type IIb c-MET kinase inhibitor that Kairos Pharma agreed in a term sheet to acquire from Celyn Therapeutics for development in c-MET-driven solid tumors, especially NSCLC with MET exon 14 skipping or MET amplification.
Has Kairos closed the CL-741 acquisition?
Public Business Wire and SEC materials describe a signed term sheet and planned 2026 clinical milestones. Closing still depends on definitive agreements and customary conditions, so teams should not treat the asset as fully owned until a closing 8-K says so.
What is the near-term clinical catalyst?
Management has highlighted initiation of a Phase 1 study of CL-741 in EGFR-mutated lung cancer during 2026, alongside ongoing ENV-105 trials in prostate cancer and NSCLC.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for CL-741.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…